First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers.On track for commercial launch in the U.S. in the ...

The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

Here’s a look at Zika virus, an illness spread through mosquito bites that can cause birth defects and other neurological defects. Facts Sources: Centers for Disease Control and Prevention (CDC), ...

Three species of mosquito are of particular concern in Europe, according to the European Centre for Disease Prevention and ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing chikungunya disease ... people developing symptoms within three ...

Summer brings warmer temperatures and longer days, and of course that means spending more time outdoors. Unfortunately, it ...

Pune: The western Indian city of Pune is seeing an unusually large cluster of cases of a paralysing neurological disorder, in ...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention ...

Bavarian Nordic (OTCPK:BVNRY) has received FDA approval for its vaccine Vimkunya for the prevention of chikungunya. The virus-like particle, or VLP, vaccine is approved for people aged 12 and older.

Guillain-Barre Syndrome (GBS) is a rare neurological disorder in which the body’s immune system mistakenly attacks the ...